American Cannabis Company Inc (AMMJ)

[hotstocks-agent]

July 25, 2006 - 8:00 AM EST


Amalfi Research Group Initiates Coverage of NatureWell, Inc.
SAN DIEGO, July 25 /PRNewswire-FirstCall/ -- NatureWell, Incorporated (the 'Company') (OTC Bulletin Board: NAWL), a manufacturer of a patented, clinically tested, over-the-counter homeopathic drug, MigraSpray, which provides relief from migraine pain and other associated symptoms, today announced that Amalfi Research Group, Ltd. has initiated coverage of the Company. The entire comprehensive report can be viewed by visiting http://www.amalfiresearch.com.

Amalfi Research Group, Ltd. is a highly specialized provider of market intelligence, high quality analytical reports, and strategic advisory services for the capital markets. Cumulatively, the Amalfi Research team has amassed more than 30 years of experience across a wide variety of business areas including strategic market analysis and securities trading, corporate research, technology consulting, and direct mail/internet marketing. Amalfi Research is strongly devoted to the research and analysis of the often overlooked intricacies and nuances of emerging small cap organizations. Through comprehensive research reports and frequent Internet research updates, Amalfi Research is able to provide the most thorough coverage of the small cap and blue chip markets.

Recent Amalfi Research Reports include: US Energy Initiatives Corp. (formerly Hybrid Fuel Systems, Inc.), General Motors, Commerce Planet, Inc. (formerly NeWave, Inc.), Nighthawk Systems, Inc. and Microsoft. For more information please contact [e-mail].

The Company currently markets its migraine relief product under the name MigraSpray, www.migraspray.com, which is a patented spray formulation, delivered sublingually, containing the herb feverfew, intended to provide fast relief and prevention from pain and other symptoms associated with migraine headaches. NatureWell, www.naturewell.com, is an emerging company engaged in the development, marketing and licensing of unique, proprietary healthcare products.

Statements made in this news release should be considered forward-looking and subject to various risks and uncertainties. Such forward-looking statements are based on management's beliefs and assumptions regarding information currently available, and are made pursuant to the 'safe harbor' provisions of the federal securities laws. The Company's actual performance and results could differ materially from those expressed in the forward-looking statements due to certain risks and uncertainties that could materially impact the Company in an adverse fashion and are only predictions of future results, and there can be no assurance that the Company's actual results will not materially differ from those anticipated in these forward-looking statements. Such risks and uncertainties, include, but are not limited to, the Company's ability to secure adequate financing, the Company's ability to ship its products in a timely fashion, volume and timing of orders received, interruption of the manufacturing or distribution of the Company's products or of the supplies or ingredients used to manufacture the Company's products, the effectiveness of the Company's products and consumer perception as to the effectiveness of the products, competitive pricing pressures and the Company's ability to anticipate changes in the market. The Company has no obligation to publicly update or revise any of the forward-looking statements that may be in this news release.

SOURCE NatureWell, Incorporated



Source: PR Newswire (July 25, 2006 - 8:00 AM EST)

News by QuoteMedia
www.quotemedia.com